Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation

Announcement for the company to issue ordinary shares through rights offering

Announcement of capital change registration for the treasury share retirement

The board of directors have resolved not to distribute dividends for 2018

The Board of Directors resolved to hold 2019 Annual General Meeting

Change of accountant due to internal adjustment of the accounting firm

Board of Directors approved the Company’s 2018 individual and consolidated financial statements

Announcement of the resolution of the treasury shares and the establishment of the base date for capital reduction by board of directors

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of Ukraine

Clarification on the collaborative publication by OBI Pharma Inc. and Academia Sinica